Evidence map›Paper›PMID 41339542›Full record

ArticleNPJ precision oncology2025

AI-driven multi-omics integration of cancer-associated fibroblasts for prognostic modeling and therapeutic target discovery in head and neck squamous cell carcinoma.

Ning Zhao, Jingru Zhang, Tianyi Sun, Xinyue Zhang, Jingyang Liu, Hanbing Yu, Hongyang Zhang

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ning Zhao *Department of Otolaryngology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Jingru Zhang *Department of Otolaryngology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Tianyi Sun *Department of Youth League Committee, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xinyue Zhang *China Medical University, Shenyang, Liaoning, China.
Jingyang LiuChina Medical University, Shenyang, Liaoning, China.
Hanbing YuDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang, Liaoning, China. yyyhhhbbb888@163.com.
Hongyang ZhangDepartment of Otolaryngology, The First Hospital of China Medical University, Shenyang, Liaoning, China. hyzhang91@cmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Head and Neck Squamous Cell Carcinoma (HNSCC), arising from the mucosal epithelium of the oral cavity, pharynx, and larynx, continues to represent a major worldwide health burden due to its high mortality rates and late-stage diagnosis. A contribution of this study is the focus on the heterogeneity of CAFs, which directly impacts therapeutic response and resistance. To address this, we applied an AI-driven, multi-omics integration strategy to elucidate CAF-mediated mechanisms in HNSCC progression and therapy. Bulk transcriptomic data from Gene Expression Omnibus (GEO) were intersected with curated CAF gene sets to identify CAF-related differentially expressed genes (CAFs-DEGs). To create a fibroblast-associated prognosis signature, a machine learning-based LASSO-Cox regression model has been developed using the TCGA-HNSCC cohort. Prognostic performance was validated through Kaplan-Meier survival analysis, time-dependent ROC, nomogram, Decision Curve Analysis (DCA), and calibration curves. To provide mechanistic insights, immune infiltration profiling, checkpoint correlations, single-cell expression mapping, tumor mutational burden (TMB), microsatellite instability (MSI), and DNA methylation analyses were performed. Furthermore, therapeutic vulnerabilities were explored by integrating drug sensitivity prediction, AI-assisted cMAP screening, and molecular docking validation, which identified Epothilone B as a promising agent targeting HBEGF. Overall, this research shows that understanding the heterogeneity of CAFs with AI-enabled multi-omics modeling can reveal prognostic biomarkers and therapeutic targets for overcoming resistance, with the ultimate goal of improving precision oncology for HNSCC.

Identifiers

PMID41339542
PMCPMC12775109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.